CN116473957A - Application of STING inhibitor C176 in preparation of medicine for preventing and treating age-related macular degeneration - Google Patents
Application of STING inhibitor C176 in preparation of medicine for preventing and treating age-related macular degeneration Download PDFInfo
- Publication number
- CN116473957A CN116473957A CN202210973977.6A CN202210973977A CN116473957A CN 116473957 A CN116473957 A CN 116473957A CN 202210973977 A CN202210973977 A CN 202210973977A CN 116473957 A CN116473957 A CN 116473957A
- Authority
- CN
- China
- Prior art keywords
- sting
- macular degeneration
- related macular
- age
- retina
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010064930 age-related macular degeneration Diseases 0.000 title claims abstract description 52
- 208000002780 macular degeneration Diseases 0.000 title claims abstract description 51
- 239000003814 drug Substances 0.000 title claims abstract description 24
- JBIKQXOZLBLMKI-UHFFFAOYSA-N n-(4-iodophenyl)-5-nitrofuran-2-carboxamide Chemical compound O1C([N+](=O)[O-])=CC=C1C(=O)NC1=CC=C(I)C=C1 JBIKQXOZLBLMKI-UHFFFAOYSA-N 0.000 title abstract description 9
- 238000002360 preparation method Methods 0.000 title description 6
- 210000001525 retina Anatomy 0.000 claims abstract description 50
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 35
- 230000000694 effects Effects 0.000 claims abstract description 21
- 230000014509 gene expression Effects 0.000 claims abstract description 21
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 17
- 210000002865 immune cell Anatomy 0.000 claims abstract description 12
- 230000004913 activation Effects 0.000 claims abstract description 11
- 230000002776 aggregation Effects 0.000 claims abstract description 9
- 238000004220 aggregation Methods 0.000 claims abstract description 9
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 40
- 229940032753 sodium iodate Drugs 0.000 claims description 37
- 235000015281 sodium iodate Nutrition 0.000 claims description 37
- 239000011697 sodium iodate Substances 0.000 claims description 37
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 18
- 230000019491 signal transduction Effects 0.000 claims description 18
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 claims description 11
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 claims description 11
- 102000004889 Interleukin-6 Human genes 0.000 claims description 11
- 108090001005 Interleukin-6 Proteins 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 8
- 229940100601 interleukin-6 Drugs 0.000 claims description 8
- 108010014726 Interferon Type I Proteins 0.000 claims description 7
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 7
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 7
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims description 6
- 102000002227 Interferon Type I Human genes 0.000 claims description 6
- 230000028709 inflammatory response Effects 0.000 claims description 5
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000026792 palmitoylation Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 238000010172 mouse model Methods 0.000 abstract description 6
- 210000000608 photoreceptor cell Anatomy 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 210000005252 bulbus oculi Anatomy 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000001993 wax Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 238000003125 immunofluorescent labeling Methods 0.000 description 5
- 238000010832 independent-sample T-test Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102100026720 Interferon beta Human genes 0.000 description 4
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 229940126586 small molecule drug Drugs 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 101000890626 Homo sapiens Allograft inflammatory factor 1 Proteins 0.000 description 2
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 2
- 101000756628 Mus musculus Actin, cytoplasmic 1 Proteins 0.000 description 2
- 101100179431 Mus musculus Ifnb1 gene Proteins 0.000 description 2
- 101001033286 Mus musculus Interleukin-1 beta Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003684 drug solvent Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000002288 golgi apparatus Anatomy 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- -1 small molecule compound Chemical class 0.000 description 2
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- XRILCFTWUCUKJR-INFSMZHSSA-N 2'-3'-cGAMP Chemical compound C([C@H]([C@H]1O)O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H]2N1C=NC2=C1NC(N)=NC2=O XRILCFTWUCUKJR-INFSMZHSSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 208000008069 Geographic Atrophy Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 1
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 description 1
- 102000043138 IRF family Human genes 0.000 description 1
- 108091054729 IRF family Proteins 0.000 description 1
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 101100452395 Mus musculus Il6ra gene Proteins 0.000 description 1
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101710106944 Serine/threonine-protein kinase TBK1 Proteins 0.000 description 1
- 101150037787 Sting gene Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an application of STING inhibitor C176 in preparing a medicament for preventing and treating age-related macular degeneration, belonging to the technical field of chemical medicaments. According to the invention, the STING inhibitor C176 is used for dosing age-related macular degeneration model mice, and the C176 is found to be capable of effectively inhibiting activation of a cGAS-STING signal path and inhibiting expression of inflammatory factors and aggregation of immune cells in retina, so that the activity of photoreceptor cells of retina is improved, and a guiding effect is provided for intervention and treatment of map-type wilting type age-related macular degeneration.
Description
Technical Field
The invention belongs to the technical field of chemical medicaments, and particularly relates to application of STING inhibitor C176 in preparation of a medicament for preventing and treating age-related macular degeneration.
Background
Geographic atrophy is one of the types of age-related macular degeneration, and no effective treatment is currently available. Map-like age-related macular degeneration results from progressive retinal pigment epithelium degeneration and atrophy, and permanent visual impairment due to death of photoreceptor cells caused by retinal pigment epithelium degeneration. It has been shown that although age-related macular degeneration is a multifactorial disease, the disorder of autoimmune function plays an important role in the disease development of age-related macular degeneration. Thus, immunomodulation is seen as a very promising treatment for age-related macular degeneration.
The cGAS-STING signaling pathway is an important cytoplasmic DNA sensing pathway in vivo, induces the expression of type I interferon (type I Inteferons, IFN 1), affects the immune response of the body, and plays an important role in regulating pathogen infection, tumor immunity and autoimmune diseases. Guanosine monophosphate-adenylate synthetase (cyclic guanosinemonophosphate-adenosine monophosphate synthase, cGAS) is a direct cytoplasmic DNA sensor, when cGAS recognizes DNA accumulated in the cytoplasm, cGAS binds to these DNA, the cGAS active site conformation changes, catalyzing ATP and GTP synthesis of cyclic dinucleotides (cyclic guanosine monophos-phase-adenosine monophosphate, cGAMP). cGAMP acts as a second messenger and binds to the interferon gene stimulatory factor (stimulator of interferon gene, STING) protein on the membrane of the endoplasmic reticulum (endoplasmic reticulum, ER), rapid dimerization of STING is activated, activated STING is transferred from ER to golgi apparatus, and kinases such as TANK-binding kinase 1 (tbk 1) and ikb kinase (IKK) are recruited in golgi apparatus, which phosphorylate interferon regulatory factor 3 (interferon regulatory factor, irf 3) and nuclear factor- κb (nuclear factor kappa-B, NF- κb) inhibitors ikbα, respectively. Phosphorylated IRF3 dimerizes and migrates into the nucleus, activating transcription of genes encoding type I interferons. Whereas iκbα phosphorylation results in NF- κb transfer to the nucleus and activates transcription of the pro-inflammatory cytokines interleukin-6 (il-6), tumor necrosis factor (tumor necrosis factor, TNF) and type I interferon genes, exerting an immunomodulatory effect affecting viral defense, inflammation and tumor therapy in the body. The functional enhancement mutation of STING gene can lead to serious autoimmune diseases, and in various inflammatory diseases such as cerebral apoplexy, liver and kidney injury, the inhibition of cGAS-STING signal pathway is beneficial to the alleviation and treatment of diseases. Recently, it has been found that there is a phenomenon in which the level of cGAS is increased in retinal pigment epithelium of patients with age-related macular degeneration in the form of map-like wilting reduction mouse disease model established by over-expression of a non-coding RNA (Alu RNA), cGAS causes activation of atypical inflammatory corpuscles by recognizing mitochondrial DNA in cytoplasm, whereas inhibition of cGAS-STING signaling pathway significantly down regulates inflammatory response in retinal pigment epithelium of map-like wilting reduction mouse disease model in cGAS knockout mice. Therefore, finding or developing a small molecule compound can effectively inhibit the cGAS-STING signal pathway in a map-type wilt-reducing mouse disease model, and has important practical significance.
Disclosure of Invention
Accordingly, the invention aims to provide an application of STING inhibitor C176 in preparing medicines for preventing and treating age-related macular degeneration.
The invention provides an application of C176 in preparation of STING inhibitors, wherein the structural formula of the C176 is shown as a formula I;
preferably, the STING inhibitor has the effect of inhibiting palmitoylation of STING protein and thereby inhibiting STING function.
The invention provides an application of a compound for inhibiting STING activity in preparing a medicament for preventing and/or treating age-related macular degeneration, wherein the compound for inhibiting STING is C176.
Preferably, the age-related macular degeneration comprises map-like, withered age-related macular degeneration.
Preferably, the medicament has one or more of the following effects: protecting retinopathy, inhibiting activation of cGAS-STING signaling pathway proteins in retina, inhibiting expression of inflammatory factor genes in retina, and reducing immune cell aggregation.
Preferably, the protein of the cGAS-STING signaling pathway includes cGAS, STING, P-STING and P-nfκbp65.
Preferably, the inflammatory factors include interleukin-1 beta, interleukin-6 and type I interferon B.
Preferably, the map-like withered age-related macular degeneration is caused by sodium iodate.
The invention provides an application of a compound for inhibiting STING activity in preparing a medicament for inhibiting inflammatory response in age-related macular degeneration, wherein the compound for inhibiting STING is C176.
Preferably, the medicament has the effect of inhibiting expression of inflammatory factor genes in the retina and reducing aggregation of immune cells.
The invention provides an application of C176 in preparation of STING inhibitors, wherein the structural formula of the C176 is shown as a formula I. Experiments show that in a mouse disease model of age-related macular degeneration constructed by sodium iodate injection, a cGAS-STING signal channel in eyeball retina is activated, the expression level of STING protein is increased, and after administration of C176, the activation of the cGAS-STING signal channel protein can be inhibited, and the expression of STING protein is obviously reduced.
The invention provides an application of a compound for inhibiting STING in preparing a medicament for preventing and/or treating age-related macular degeneration, wherein the compound for inhibiting STING is C176. Experiments prove that the sodium iodate-induced age-related macular degeneration mouse disease model is taken as a study object, a model control group shows typical retinopathy through physiological and biochemical detection and molecular level detection, and the administration of C176 can effectively inhibit and protect retinopathy, inhibit activation of protein of a cGAS-STING signal path in retina, can also effectively inhibit inflammatory reaction in retina, particularly inhibit expression of inflammatory factor genes in retina and reduce aggregation of immune cells, and provides a new idea for preventing and/or treating age-related macular degeneration.
The invention provides an application of a compound for inhibiting STING in preparing a medicament for inhibiting inflammatory response in age-related macular degeneration, wherein the compound for inhibiting STING is C176. The invention reports for the first time that the small molecule drug STING inhibitor C176 can inhibit the expression of inflammatory factors in eyes of mice and the immune cells gather, thereby improving the activity of retina photoreceptor cells and providing guiding effect for the intervention and treatment of map-type withered age-related macular degeneration.
Drawings
FIG. 1 is a schematic diagram showing activation of the cGAS-STING signaling pathway in retinas of sodium iodate-induced age-related macular degeneration mice disease model, FIG. 1A is a fundus image and fluorescein fundus angiography image of a control group and sodium iodate-treated group; fig. 1B shows the change in cGAS-STING signaling pathway-related protein levels in the retinas of control and sodium iodate-treated mice, with the lower half of the plot showing the results of gray scale analysis, n=5; p-value was calculated from independent sample t-test: p <0.05,: p <0.01,: p is less than 0.0001, and the error line is standard deviation; fig. 1C shows changes in expression levels of IL1 β, IL6, IFNB1 and other genes mRNA in retinas of control and sodium iodate treated mice, n=5; p-value was calculated from independent sample t-test: p <0.05,: p <0.01,: p is less than 0.0001, and the error line is standard deviation;
FIG. 2 is a graph of C176 inhibiting activation of the cGAS-STING signaling pathway in the retina of a mouse model of age-related macular degeneration induced by sodium iodate; the left panel shows western immunoblots of sodium iodate treatment and sodium iodate plus C176 dosing treatment, where 60, 40kDa, 40, 75, 60 and 35 represent molecular weights (kDa) of the respective proteins, respectively; 1 to 5 respectively represent the number of mice; the right graph is the result of gray level analysis; sodium iodate treatment group n=4, sodium iodate plus C176 group n=5; p-value was calculated from independent sample t-test: p <0.05,: p <0.01,: p is less than 0.0001, and the error line is standard deviation;
FIG. 3 shows changes in IL1 beta, IL6, IFNB1 isogenic mRNA expression levels in retinas from sodium iodate treatment groups, n=4, sodium iodate plus JQ1 dosing groups, n=5; p-value was calculated from independent sample t-test: p <0.05,: p is less than 0.01, and the error line is standard deviation;
fig. 4a. He staining indicates that C176 protects the mouse retina, inhibits sodium iodate-induced retinal structural disorders and pigment epithelial cell swelling and detachment;
FIG. 4B shows that immunofluorescent staining of frozen sections of retina indicates a decrease in IBA1 positive immune cells after C176 treatment;
FIG. 4℃ Immunofluorescent staining of retinal patches further demonstrates that IAB1 positive cells are reduced in the retina after C176 treatment; the right graph shows the statistical result after IBA1 positive cell technology; p values were calculated from independent sample t-test: p <0.01, error line is standard deviation.
Detailed Description
The invention provides an application of C176 in preparation of STING inhibitors, wherein the structural formula of the C176 is shown as a formula I;
in the present invention, the chemical name of the C176 is N- (4-iodophenyl) -5-nitrofuran-2-carboxamide, the molecular weight is 358.09, and the molecular formula is C 11 H 7 IN 2 O 4 . The source of the C176 is not particularly limited in the present invention, and sources well known in the art may be used. In the present example, the C176 is purchased from Selleck corporation as # S6575. The STING inhibitor preferably has an effect of inhibiting palmitoylation of STING protein and thus inhibiting STING function.
The invention provides an application of a compound for inhibiting STING activity in preparing a medicament for preventing and/or treating age-related macular degeneration, wherein the compound for inhibiting STING is C176.
In the present invention, the age-related macular degeneration preferably includes map-type age-related macular degeneration. The geographic-like, wilted age-related macular degeneration is preferably caused by sodium iodate. In the embodiment of the invention, healthy mice are treated with sodium iodate to obtain a map-like wilted age-related macular degeneration mouse model, which is characterized in that compared with a control group, the retina of the sodium iodate-treated mice is obviously damaged after three days of sodium iodate injection, and cGAS-STING signal channels in the retina of the mice are activated, inflammatory factor expression is increased, inflammatory cells are aggregated and the like. The map-type withered age-related macular degeneration mouse model is taken as a study object, and C176 injection can effectively protect retina injury, inhibit activation of protein of a cGAS-STING signal path in retina, inhibit expression of inflammatory factor genes in retina and reduce aggregation of immune cells. The proteins of the cGAS-STING signal pathway preferably include cGAS, STING, P-STING and P-nfκbp65. The inflammatory factors preferably include interleukin-1 beta, interleukin-6 and type I interferon B. Thus, the C176 can achieve the aim of protecting the retina injury by inhibiting the cGAS-STING signal path in the retina and inhibiting inflammatory reaction in the retina, thereby being beneficial to improving the activity of the retina photoreceptor cells and providing guiding effect for the intervention and treatment of the map-type withered age-related macular degeneration.
In the present invention, the effective dose of C176 is preferably 8 to 12 mg/kg of mice, more preferably 10mg/kg of mice. The effective concentration of C176 in the medicament is preferably 0.9-1.1 mg/ml, more preferably 1mg/ml. The dosage form of the medicament is preferably injection. The method for preparing the injection is not particularly limited, and can be any method known in the art.
The invention provides an application of a compound for inhibiting STING activity in preparing a medicament for inhibiting inflammatory response in age-related macular degeneration, wherein the compound for inhibiting STING is C176.
In the present invention, the drug preferably has effects of inhibiting the expression of inflammatory factor genes in the retina and reducing the aggregation of immune cells. The medicines are the same as those described above, and are not described in detail here.
The following examples are presented to illustrate the use of STING inhibitor C176 according to the present invention in the manufacture of a medicament for the prevention and treatment of age-related macular degeneration, but are not to be construed as limiting the scope of the invention.
Example 1
Construction of age-related macular degeneration mouse disease model and C176 administration therapy
1. The age-related macular degeneration mice disease model was established by intraperitoneal injection of sodium iodate (0.5%, PBS) at a dose of 35 mg/kg. Two hours after sodium iodate injection, C176 (1 mg/ml) was injected intraperitoneally into the C176-dosed treatment group at a dose of 10mg/kg, and the sodium iodate-treated group was intraperitoneally injected with the same volume of the drug solvent (2%DMSO,30%Polyoxy ethylene300,5%Tween80), both C176 and the drug solvent were injected for 3 days, once daily. Mice in the placebo group were injected with an equal volume of sterile Phosphate Buffer (PBS).
2 mouse retina dissection and material sampling
Three days after sodium iodate injection, all groups of mice were sacrificed by cervical removal, the eyelids of the mice were opened with one hand to protrude their eyes, and the other hand-held forceps were inserted into the eye sockets, forced upward from below the eyes, and the eyes were removed along with the optic nerve. This was placed in a 10cm cell culture dish containing PBS and dissected under a split microscope as follows: extraocular muscles and connective tissue attached to the eyeball floating in PBS were removed with an ophthalmic scissors. A small incision is made on the corner consolidating edge, the left hand-held forceps extend from the incision to clamp the cornea, the right hand-held ophthalmic scissors cut the eyeball along the corner consolidating edge, and the eyeball is divided into two parts, namely an anterior pole part (cornea, iris, lens) and a posterior optic cup (sclera, choroid and retina). The retina is peeled off from the rearview cup by forceps, the retina is filled into a centrifuge tube with the information of the name of the sample, the date of drawing the materials and the like marked in advance, the centrifuge tube is placed into liquid nitrogen for quick freezing, and the subsequent operation is carried out after the same batch of materials are taken out.
3 extraction of mouse retina protein and Western blotting experiment
200 μl of RIPA lysate containing protease inhibitor is added into a centrifuge tube containing mouse retina sample, and the tissue protein is placed into a fresh ganoderma lucidum ultrasonic instrument, and is connected with ice water circulation, and ultrasonic energy is set at 60%, total time is 1min,2 seconds is on, and 2 seconds is off. After sufficient lysis of the tissue cells, the protein supernatant was separated from other material pellet by centrifugation at 12000rpm for 10min at 4℃and the supernatant fraction was added to a centrifuge tube with the information on standard. Protein supernatant is subjected to concentration measurement by using a BCA protein concentration measurement kit, and 20-50 mug protein samples are taken for carrying out a protein immunoblotting experiment, so that the expression of cGAS-STING signal pathway related proteins (including cGAS, STING, phosphorylated STING (P-STING), phosphorylated NFKB P65 (P-NFKB P65), IL1 beta precursor (Pro-IL 1 beta) and active cutter (clear IL1 beta) proteins) in the retina of a mouse are respectively detected.
4 mouse retina RNA extraction and real-time fluorescence quantitative PCR experiment
1ml of Trizol reagent was added to a centrifuge tube containing a mouse retina sample, and the mixture was ground with an RNase-free grinding rod to obtain tissue cells, and RNA was extracted according to the Trizol reagent protocol after the tissue cells were sufficiently lysed.
1. Mu.g of RNA was taken and cDNA was synthesized using a reverse transcription kit. Real-time fluorescent quantitative PCR experiments were performed using SuperReal PreMix Plus (SYBR Green) and a fluorescent quantitative PCR instrument, and the specific procedure was as follows:
(1) RNA reverse transcription: reverse transcription of RNA was performed using HiScript II qRT SuperMix II (novzan) kit:
1) Removal of genomic DNA: the reaction solution was prepared in RNase-free PCR tubes:
template RNA 1. Mu.g, 4 XgDNA wind Mix 4. Mu.l, RNase free ddH 2 O was supplemented to 16. Mu.l.
Placing the prepared reaction solution into a PCR instrument at 42 ℃ for 2min;
2) Reverse transcription reaction: to the reaction mixture in 1), 4. Mu.l of 5X HiScript II qRT SuperMix II was added, and the mixture was blown and mixed, and then placed in a PCR apparatus, and the PCR program was set at 55℃for 15min and 85℃for 5sec.
(2) Real-time fluorescent quantitative PCR: fluorescent real-time quantitative PCR was performed using a 2X ChamQTM SYBR Color qPCR Master Mix (Norflu) kit, and the specific steps are as follows:
1) Preparing a PCR reaction solution:
4.5. Mu.l of cDNA template, 2X SYBR qPCR Master Mix. Mu.l of 10. Mu. M F +R primer (specific sequence as follows) and 0.5. Mu.l of each.
The primers of the detected target genes are as follows:
mouse IL-1β F TGCAGACTCAAACTCC (SEQ ID NO: 1);
mouse IL-1β R TGAAAGACGGCACACC (SEQ ID NO: 2);
mouse IL-6F GTTCTCTGGGAAATCGTGG (SEQ ID NO: 3);
mouse IL-6R CTGCAAGTGCATCATCGTT (SEQ ID NO: 4);
mouse IFNB F CTCCAGCTCCAAGAAAGGAC (SEQ ID NO: 5);
mouse IFNB R TGGCAAAGGCAGTGTAACTC (SEQ ID NO: 6);
the internal reference gene is Beta ACTIN, and specific primers are as follows:
mouse BetaACTIN F CCTAAGGCCAACCGTGAAAA (SEQ ID NO: 7);
mouse Beta ACTIN R CAGAGGCATACAGGGACAGC (SEQ ID NO: 8).
The prepared PCR reaction solution is added into a 384-well plate, 3 multiple wells are repeated for each sample, and after the sample application is finished, the 384-well plate is placed into a centrifuge for centrifugation at 2500rpm for 5min. Real-time fluorescent quantitative PCR reactions were performed using the rosen LightCycler 480 II, with the program set to: pre-denaturation at 94℃for 5min, denaturation at 94℃for 10s, annealing at 58℃for 20s, extension at 72℃for 20s, and single fluorescence signals were collected by the machine during the extension phase. Analyzing the data after the instrument is operated, using ACTB (beta actin) as an internal reference gene, and applying 2 -ΔΔCt The ratio of the mRNA expression quantity of the target gene to the mRNA expression quantity of the reference gene is calculated by the method, and the relative quantification is carried out.
5. HE staining, immunohistochemistry and immunofluorescence staining of mouse eye tissues. Taking eyeballs, putting the eyeballs into PBS for washing for one time, and puncturing a small opening at the cornice edge by using a syringe, so that the entrance of a fixing solution is facilitated; placing the eyeball in a 2ml EP tube, adding 1ml of FAS eyeball fixing solution, and fixing at room temperature overnight; dehydrating: sequentially placing the fixed eyeball into 50%, 60%, 70%, 80%, 90%, 95% ethanol for 1 time each for 30min, and anhydrous ethanol for two times each for 30min; and (3) transparency: sequentially placing dehydrated eyeballs in an absolute ethyl alcohol-xylene=1:1 solution for 15min, and performing xylene twice for 15min each time; wax dipping: sequentially placing eyeball tissues in low-melting-point wax I at 55deg.C for 30min, low-melting-point wax II at 55deg.C for 90min, and high-melting-point wax at 60deg.C for 90min; embedding: according to the longitudinal cutting direction of the eyeball, horizontally placing the eyeball along the direction of the cornea optic nerve axis, firstly adding a thin layer of wax to hold the eyeball, slowly adding the rest wax after the lower layer of wax is solidified to uniformly fill the embedding frame, and slicing after the wax is completely solidified and is frozen overnight in a refrigerator at minus 20 ℃; slicing: slicing by using a paraffin slicer, wherein each slice has a thickness of 8 mu m, and placing the paraffin slices into a water bath kettle at 40 ℃ for spreading; selecting cut slices, placing the slices in a slide clamp, and drying the slices in an oven at 60 ℃ for 2 hours; the dried slide was stored at minus 20 ℃.
6. Experimental results
6.1 activation of the cGAS-STING signaling pathway in retinas of sodium iodate-induced age-related macular degeneration mouse disease models
The disease model of age-related macular degeneration mice was successfully established by intraperitoneal injection of sodium iodate (dosage of 35 mg/kg) into mice. As shown in fig. 1A, three days after sodium iodate injection, the retinas of sodium iodate-treated mice appeared to be significantly damaged compared to the control group. And we found through western blotting experiments and real-time fluorescent quantitative PCR experiments that cGAS-STING signaling pathway was activated in the retinas of mice in the sodium iodate treatment group, and that the inflammatory factors interleukin-1β (interleukin-1β, IL-1β), interleukin-6 (interleukin 6, IL-6), and type I interferon B (type I Inteferons, IFNB 1) were up-regulated, as compared to the control group, as shown in fig. 1B and 1C.
6.2 C176 may inhibit activation of the cGAS-STING signaling pathway protein in the retina of a mouse model of age-related macular degeneration induced by sodium iodate.
Mice with age-related macular degeneration induced by sodium iodate were intraperitoneally injected with the small molecule drug C176 at a dose of 10mg/kg. Western immunoblotting experiments show that the C176 treatment can significantly reduce the expression of cGAS-STING signal pathway related proteins (phosphorylated STING (P-STING), phosphorylated NFKB (P-NFKB) and phosphorylated TBK1 (P-TBK 1)) in the retina of the mouse.
6.3 C176 can inhibit the expression of the inflammatory factors interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6) and Interferon (Interferon beta, IFNB 1) genes in the retina of a mouse model of age-related macular degeneration induced by sodium iodate.
Mice with age-related macular degeneration induced by sodium iodate were intraperitoneally injected with the small molecule drug C176 at a dose of 10mg/kg. Real-time quantitative PCR experiments show that the C176 treatment can significantly reduce the expression of inflammatory factor related genes in the retina of mice.
6.4 C176 can inhibit retinal degeneration and immune cell aggregation in a mouse disease model of age-related macular degeneration induced by sodium iodate.
Mice with age-related macular degeneration induced by sodium iodate were intraperitoneally injected with the small molecule drug C176 at a dose of 10mg/kg. As shown in fig. 4A to 4C, C176 protected the retina of the mouse, and inhibited retinal structural disturbance and pigment epithelial cell swelling and detachment caused by sodium iodate. Immunofluorescent staining of frozen sections of retina showed that IBA 1-positive immune cells were reduced after C176 treatment. Immunofluorescent staining of retinal patches further showed that IAB1 positive cells were reduced in the retina after C176 treatment.
From the results of the above examples, it is known that the small molecular compound C176 has a protective effect on retinal damage caused by sodium iodate injection, and the invention proves for the first time that the small molecular compound C176 achieves the effect of preventing and treating age-related macular degeneration diseases by inhibiting cGAS-STING signaling pathway and downstream inflammatory reaction.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (10)
1. The application of C176 in preparing STING inhibitor, wherein the structural formula of C176 is shown in formula I;
2. the use according to claim 1, wherein said STING inhibitor has the effect of inhibiting palmitoylation of STING proteins and thereby inhibiting STING function.
3. Use of a compound that inhibits STING activity, wherein the compound that inhibits STING is C176, in the manufacture of a medicament for the prevention and/or treatment of age-related macular degeneration.
4. The use according to claim 3, wherein the age-related macular degeneration comprises map-like, withered age-related macular degeneration.
5. The use according to claim 4, wherein the medicament has one or more of the following effects: protecting retinopathy, inhibiting activation of cGAS-STING signaling pathway proteins in retina, inhibiting expression of inflammatory factor genes in retina, and reducing immune cell aggregation.
6. The use according to claim 5, wherein the cGAS-STING signaling pathway proteins include cGAS, STING, P-STING and P-nfκ B P65.
7. The use according to claim 5, wherein the inflammatory factors include interleukin-1 beta, interleukin-6 and type I interferon B.
8. The use according to any one of claims 4 to 7, wherein the map-like age-related macular degeneration is caused by sodium iodate.
9. Use of a compound that inhibits STING activity, wherein the compound that inhibits STING is C176, in the manufacture of a medicament for inhibiting inflammatory responses in age-related macular degeneration.
10. The use according to claim 9, wherein the medicament has the effect of inhibiting the expression of inflammatory factor genes in the retina and reducing the aggregation of immune cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210973977.6A CN116473957A (en) | 2022-08-15 | 2022-08-15 | Application of STING inhibitor C176 in preparation of medicine for preventing and treating age-related macular degeneration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210973977.6A CN116473957A (en) | 2022-08-15 | 2022-08-15 | Application of STING inhibitor C176 in preparation of medicine for preventing and treating age-related macular degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116473957A true CN116473957A (en) | 2023-07-25 |
Family
ID=87225553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210973977.6A Pending CN116473957A (en) | 2022-08-15 | 2022-08-15 | Application of STING inhibitor C176 in preparation of medicine for preventing and treating age-related macular degeneration |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116473957A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3502102A1 (en) * | 2017-12-20 | 2019-06-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Sting inhibitors |
| CN112546049A (en) * | 2020-12-22 | 2021-03-26 | 中山大学中山眼科中心 | Application of small molecule medicine (+) -JQ1 in preparation of medicine for treating pattern-collapse-type age-related macular degeneration |
-
2022
- 2022-08-15 CN CN202210973977.6A patent/CN116473957A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3502102A1 (en) * | 2017-12-20 | 2019-06-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Sting inhibitors |
| CN112546049A (en) * | 2020-12-22 | 2021-03-26 | 中山大学中山眼科中心 | Application of small molecule medicine (+) -JQ1 in preparation of medicine for treating pattern-collapse-type age-related macular degeneration |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Anti‐inflammatory effects of berberine hydrochloride in an LPS‐induced murine model of mastitis | |
| CN110731955A (en) | Application of dimethyl itaconate in preventing and treating ulcerative colitis and canceration thereof | |
| Jia et al. | Long noncoding ribonucleic acid NKILA induces the endoplasmic reticulum stress/autophagy pathway and inhibits the nuclear factor‐k‐gene binding pathway in rats after intracerebral hemorrhage | |
| CN113633642A (en) | Application of ABT-263 in preparation of medicine for inhibiting corneal transplantation immune rejection | |
| Kiyota et al. | Effect of androgen on the expression of the sex difference in susceptibility to infection with Strongyloides ratti in C57BL/6 mice | |
| US20070004767A1 (en) | Methods for treating neurofibromatosis 1 | |
| WO2017181857A1 (en) | Composition for fat reduction and liver protection, and application thereof | |
| CN116473957A (en) | Application of STING inhibitor C176 in preparation of medicine for preventing and treating age-related macular degeneration | |
| CN112546049A (en) | Application of small molecule medicine (+) -JQ1 in preparation of medicine for treating pattern-collapse-type age-related macular degeneration | |
| CN114887063A (en) | Application of Pacsin1 in inhibition of remifentanil-induced hyperalgesia | |
| CN113350371A (en) | Research on inhibition effect of gas neuroprotective agent on NLRP3 inflammation corpuscle and application thereof | |
| CN110624108B (en) | Application of Fas or ligand FasL thereof as target in preparation of antitumor drugs | |
| CN107529558B (en) | New application of polynucleotide-5 'kinase-3' phosphatase | |
| WO2018228430A1 (en) | Use of isoferulic acid, isoferulic acid-containing traditional chinese medicine extract and cimicifugae foetidae | |
| CN113230250A (en) | Application of dexmedetomidine in preparing pharmaceutical composition for improving diabetic peripheral neuropathy | |
| CN114099515A (en) | Application of methotrexate in preparation of medicine for treating retinitis pigmentosa | |
| CN114767710B (en) | Application of ferrous glycinate in treating rheumatoid arthritis | |
| CN110755621B (en) | Composition containing Senp expression regulating reagent and application of composition in preparation of anti-hepatic fibrosis medicine | |
| CN113337594B (en) | Application of LPCAT1 gene in preparation of medicine for treating liver inflammation and diagnostic kit | |
| Chen et al. | N6-Methyladenosine-Modification-Related Ophthalmic Diseases and Potential Therapeutic Strategies | |
| KR102415950B1 (en) | Health functional food for eye comprising mixture of chrysanthemum extract, quince extract, and longan meat extract as an active ingredient and manufacturing method thereof | |
| CN109985046A (en) | - 3 beta, 5,6 beta-triol of 5 α-androstane is used for the treatment of inflammation mediated optic neuropathy | |
| AU686842B2 (en) | Method of treating birds with avian myelomonocytic growth factor | |
| CN106581151B (en) | Application of traditional Chinese medicine composition for promoting blood circulation and removing stasis | |
| Pu et al. | Effects of tetrandrine pretreatment on spinal cord ischemia-reperfusion injury in rabbits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |